Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02824419|
Recruitment Status : Unknown
Verified July 2016 by Turku University Hospital.
Recruitment status was: Recruiting
First Posted : July 6, 2016
Last Update Posted : July 6, 2016
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Sarcoidosis||Drug: Methionine Drug: DOTANOC||Phase 2 Phase 3|
The diagnosis of sarcoidosis is difficult since there is no specific noninvasive method available to diagnose sarcoidosis. FDG-PET imaging is in use, however, FDG is not a specific tracer for sarcoidosis and other inflammatory diseases may interfere with the imaging findings. The aim of the current protocol is to evaluate the potential of other inflammatory PET-tracers in the detection of sarcoidotic lesions.
The patients with active sarcoidotic lesions in lungs will be recruited. First, the patient undergoes PET-FDG scan and then the patient undergoes the PET scan either with C11-methionine or 68Ga-DOTANOC. The results with the latter tracers will be compared to the imaging results with FDG.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis|
|Study Start Date :||May 2016|
|Estimated Primary Completion Date :||May 2017|
|Estimated Study Completion Date :||December 2017|
To compare FDG and C11-methionine in the detection of sarcoidotic lesions.
Subject undergoes imaging studies with FDG and with methionine.
Other Name: PET tracers
To compare FDG and 68Ga-DOTANOC in the detection of sarcoidotic lesions.
Subject undergoes imaging studies with FDG and with DOTANOC.
Other Name: PET tracers
- The detection of sarcoidotic lesion with C11-methionine or 68Ga-DOTANOC. [ Time Frame: baseline ]Qualitative assessment of tracer uptake in sarcoidotic lesions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02824419
|Contact: Riikka Lautamaki, MD, PhD||+3582 email@example.com|
|Turku University Hospital||Recruiting|
|Turku, Varsinais-Suomi, Finland, 20520|
|Contact: Riikka Lautamaki, MD, PhD +358 2 313 0000 firstname.lastname@example.org|
|Contact: Juhani Knuuti, MD, PhD +358 2 313 0000|
|Principal Investigator:||Juhani Knuuti, MD, PhD||Turku PET Centre, Turku University Hospital, Turku, Finland|